News - Nimotuzumab
2011-12-12 16:00:00
- Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported - - Well tolerated for dosing periods up to and exceeding two years - - MRI results confirm
2011-10-31 06:00:00
- Phase II Study of Nimotuzumab in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma (DIPG) MISSISAUGA, ON, Oct.
2011-10-19 06:00:00
- Company announces Annual and Special Meeting of Shareholders and appoints new head of Strategic Alliances - MISSISAUGA, ON, Oct.